Skip to main content

Table 1 proportion of clinicopathologic and IHC defined subtypes of BC in Eritrean and Sudanese women

From: Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series

Clinical and tumour characteristics Origin Combined both study groups
Eritrean Sudanese
n % n % n %
Histologic type IDCNST 89 76.7% 492 87.9% 581 85.9%
ILC 11 9.5% 18 3.2% 29 4.3%
others 16 13.8% 50 8.9% 66 9.8%
Pathologic tumour size pT1 23 19.8% 82 15.5% 105 16.3%
pT2 48 41.4% 248 47.0% 296 46.0%
pT3 37 31.9% 118 22.3% 155 24.1%
pT4 8 6.9% 80 15.2% 88 13.7%
LN involvement pN0 72 62.1% 198 47.3% 270 50.5%
pN1(1–3) 15 12.9% 86 20.5% 101 18.9%
pN2(3–9) 16 13.8% 78 18.6% 94 17.6%
pN3(>9) 13 11.2% 57 13.6% 70 13.1%
Grading GI 10 8.6% 20 3.6% 30 4.4%
GII 46 39.7% 306 54.6% 352 52.1%
GIII 60 51.7% 234 41.8% 294 43.5%
LVI NO 44 37.9% 264 46.9% 308 45.2%
unknown 6 5.1% 111 19.8% 117 17.3%
YES 56 48.3% 185 15.2% 102 35.5%
ER ER negative. 59 50.9% 308 55.0% 367 54.3%
ER positive. 57 49.1% 252 45.0% 309 45.7%
PR PR negative 69 59.5% 346 61.8% 415 61.4%
PR positive 47 40.5% 214 38.2% 261 38.6%
HR HR positive 57 49.1% 257 45.9% 314 46.4%
HR negative 59 50.9% 303 54.1% 362 53.6%
HER2 negative 82 70.7% 296 71.3% 378 71.2%
positive 34 29.3% 119 28.7% 153 28.8%
  Missing 0 0 147 147
IHC based breast cancer subtype Luminal A-like 43 37.1% 153 36.9% 196 36.9%
Luminal B-like 14 12.1% 54 13.0% 68 12.8%
HER2 enriched 20 17.2% 65 15.7% 85 16.0%
TNBC 39 33.6% 143 34.5% 182 34.3%
  1. IDCNST invasive ductal carcinoma, no special type, ILC invasive lobular carcinoma, TNBC Triple negative Breast cancer